Clinical trials: Type One Diabetes Mellitus
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2…
- Trial name
- NCT06972459
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™
The purpose of this trial is to evaluate the long-term safety in subjects previously implanted with VC-01™ combination product.
- Trial name
- NCT02939118
- Volunteers
- 51 people
- Sponsor
- ViaCyte
Diabetes Mellitus, Type 2
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes…
- Trial name
- NCT00601250
- Testing
- linagliptin
- Where
- 82 sites in United States, Czechia and 8 more
- Volunteers
- 701 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Diabetic Nephropathies
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease.
- Trial name
- NCT00168857
- Testing
- telmisartan, losartan
- Where
- 109 sites in United States, Argentina and 8 more
- Volunteers
- 860 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering…
- Trial name
- NCT06731075
- Testing
- ORMD-0801 8 mg, ORMD-0801 16 mg
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Oramed, Ltd.
Pregestational Diabetes, Continuous Glucose Monitoring
CGM Accuracy in Pregnancy Study
Pregnancy in women with diabetes remains a high-risk condition, requiring strict glycemic control due to rapid physiological changes that affect insulin sensitivity.
- Trial name
- NCT07269015
- Testing
- Dexcom One Plus, FreeStyle Libre 2 Plus, Additional Study Procedures
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- Hospital Mutua de Terrassa
Type 1 Diabetes Mellitus
Prevalence and Incidence of Complications of Type One Diabetes in PUne At a Tertiary Care CentRE
Due to early diagnosis (<20yrs of age) of Type 1 Diabetes, patients face longer duration of disease and greater glycemic exposure which makes them more vulnerable towards chronic complications.
- Trial name
- PICTURE (NCT03069196)
- Where
- India
- Volunteers
- 323 people
- Sponsor
- Kem Hospital, Pune, India
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Type 1 Diabetes Mellitus
Omega-3 and Vitamin D Supplements in Childhood T1D
The study was conducted in 64 patients with T1D of which 26 had the onset in 2017, and 38 in 2016, 2015 and 2014. All received vitamin D 1000 IU /day since disease's onset.
- Trial name
- NCT03911843
- Testing
- omega-3 supplementation, Vitamin D supplementation
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Diabetes Mellitus
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00134147
- Testing
- Inhaled Insulin
- Where
- 121 sites in United States, Canada and 5 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- AZD6234
- Where
- 212 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type I
The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children
The purpose of this study is to see if the use of a real-time glucose sensor improves diabetes control in young children (less than 4 years old) with Type I diabetes when they are initiated on insulin pump therapy.
- Trial name
- Gerber RTSA (NCT00875290)
- Testing
- Real-time glucose sensor
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Children's Hospital
Diabetic Nephropathies, Hypertension
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure beyond the target of 130/80 mmHg after one year…
- Trial name
- NCT00153023
- Testing
- Telmisartan, Valsartan
- Where
- 111 sites in Czechia, Denmark and 11 more
- Volunteers
- 885 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Healthy Subjects
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal…
- Trial name
- NCT03802487
- Testing
- Sotagliflozin (SAR439954), 14C-microtracer, Charcoal
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administered at a dose of 25 mg once…
- Trial name
- TRACK (NCT02771093)
- Testing
- Trelagliptin, Alogliptin
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Diabetes Mellitus, Group Meetings
Group Versus Individual Care in Diabetes Clinic
In this prospective, randomized, non blinded, one center (University hospital) trial, 60 patients (28 with type 1 and 32 with type 2 diabetes) with a mean duration of diabetes of 22.5 ± 11.7 years were randomly assigned to group…
- Trial name
- NCT03353376
- Testing
- group care with Empowerment model
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Diabetes Mellitus, Type 2
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period.
- Trial name
- LANCELOT (NCT00949442)
- Testing
- Insulin Glargine (HOE901) [Lantus], Glimepiride, human insulin [NPH]
- Where
- 87 sites in Brazil, Czechia and 15 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
13-18 Year, Diagnosed at Least 6 Months Ago
Metabolic Control Adolescents Type 1 Diabetes
Purpose of the research; The aim of this study is to examine the effect of education including peer-interactive group support to be given to adolescents diagnosed with Type 1 diabetes with poor glycemic control in the 13-18 age…
- Conditions
- 13-18 Year, Diagnosed at Least 6 Months Ago, HbA1C> 7.5, Being Able to Read and Write
- Trial name
- NCT05811078
- Testing
- training sessions with peer interactive group
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Toros University
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2…
- Trial name
- SUSTAIN™ (NCT02207374)
- Testing
- semaglutide, DPP-4 inhibitor
- Where
- 43 sites in Japan
- Volunteers
- 601 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes
Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes
To evaluate the safety and efficacy of Stem Cells From Human Exfoliated Teethtransplantation in patients with type 2 diabetes to provides scientific basis for further clinical studies to verify the safety and efficacy of type 2…
- Trial name
- NCT03658655
- Testing
- Stem Cells From Human Exfoliated Teeth
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.